Results 181 to 190 of about 23,125,138 (369)
Interleukin-2 is a potent latency reversal agent in people with treated HIV-1. [PDF]
Freeman ML +10 more
europepmc +1 more source
An advanced microneedle patch integrating niobium carbide nanosheets and curcumin is engineered for diabetic wound healing. The system enables dual ROS scavenging and NIR‐enhanced antimicrobial activity, effectively rebalancing the oxidative microenvironment, promoting macrophage repolarization and angiogenesis, and accelerating full‐thickness wound ...
Zhi Zheng +12 more
wiley +1 more source
Analysis of Soluble Interleukin-2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD. [PDF]
Klyscz P +8 more
europepmc +1 more source
Case Report: Development of Hodgkin's Disease in Patient Receiving Long-Term Administration of Dacarbazine and Interleukin-2 for Metastatic Melanoma [PDF]
L. E. FLAHERTY +3 more
openalex +1 more source
Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.
W. Liao, Jian-Xin Lin, W. Leonard
semanticscholar +1 more source
This work offers unique Ginger‐based 3D‐printable resins that can print customizable high‐resolution complex designs. The customizable printing backbone of Zingerol prints also mimics various human bones' strength. Acquisition of in‐vivo biocompatibility in rat model with no severe inflammatory response, along with in‐vitro antioxidant and ex‐vivo anti‐
Simran Jindal +9 more
wiley +1 more source
The Predictive Significance of Interleukin-2 Receptor in Patients with Hepatocellular Carcinoma. [PDF]
Tian Z, Guo Y, Yang R, Yang W.
europepmc +1 more source
Interleukin-2: Biology, Design and Application.
Natalia Arenas-Ramirez +2 more
semanticscholar +1 more source
Detecting proteins secreted by a single cell while retaining its viability remains challenging. A particles‐in‐particle (PiPs) system made by co‐encapsulating barcoded microparticles (BMPs) with a single cell inside an alginate hydrogel particle is introduced.
Félix Lussier +10 more
wiley +1 more source
Efficacy and safety of low-dose interleukin 2 for Behçet's syndrome: a randomized, placebo-controlled, double-blind, phase 2 clinical trial. [PDF]
Liu T +28 more
europepmc +1 more source

